mycophenolate mofetil / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

152 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mycophenolate mofetil / Generic mfg.
MoTD, NCT04888741 / 2019-002419-24: Methods of T Cell Depletion Trial

Recruiting
2
400
Europe
Thymoglobulin, ATG, Cyclophosphamide, Cyclosporine, Sirolimus, Mycophenolate Mofetil, MMF
University of Birmingham, IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelofibrosis
01/26
01/26
NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation

Completed
2
13
US
TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
10/23
10/23
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Recruiting
2
60
US
Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis
Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.
Acute Myeloid Leukemia
01/26
01/26
OPTIMIZE, NCT06001385: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Recruiting
2
190
US
Busulfan, Busulfex®, Fludarabine, Fludara®, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, PBSCT, Post-Transplant Cyclophosphamide, Cytoxan®, PTCy, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient Reported Outcomes, PRO, Melphalan, Total-body irradiation, TBI, Cyclophosphamide
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
02/26
06/26
NCT05736419: A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Recruiting
2
24
US
Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab
Memorial Sloan Kettering Cancer Center
Sickle Cell Disease, Thalassemia, Beta, Thalassemia
02/26
02/26
POSTERITY, NCT05039619 / 2021-000097-29: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Recruiting
2
40
Europe, Canada, US, RoW
Obinutuzumab, Gazyva, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Hoffmann-La Roche, Genentech, Inc.
Lupus Nephritis
03/26
03/29
NCT06019507: A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Recruiting
2
12
Europe
TCD601, siplizumab, Cyclophosphamide, TAC, Tacrolimus, MMF, Mycophenolate Mofetil, Corticosteroids
ITB-Med LLC
Liver Transplantation
06/26
06/29
NCT03663933: Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Recruiting
2
177
US
Immunosuppression Only Conditioning, Reduced Intensity Conditioning, GVHD Prophylaxis, Allogeneic HSC
National Cancer Institute (NCI)
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases, Common Variable Immunodeficiency
07/26
01/31
NCT05843968: Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome

Recruiting
2
46
RoW
Rituximab, Rituximab Injection, Mycophenolate Mofetil, Mycophenolate Mofetil Dispersible tablets
Children's Hospital of Chongqing Medical University
Nephrotic Syndrome in Children
07/26
07/26
NCT05027945: A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Suspended
2
3
US
Post-Transplant Cyclophosphamide (PTCY), Cyclophosphamide (CY), Fludarabine, Total Body Irradiation (TBI), Busulfan, Sirolimus, Mycophenolate mofetil (MMF), Busulfan test dose, Allogeneic HSCT
National Cancer Institute (NCI)
Immunodeficiency, Hematopoietic Stem Cell Transplantation
07/26
07/26
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
SATELITE, NCT04871191: Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

Not yet recruiting
2
42
Europe
Rituximab, Mabthera, Tocilizumab, RoActemra, Abatacept, Orencia
Assistance Publique - Hôpitaux de Paris, URC-CIC Paris Descartes Necker Cochin
Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
09/26
01/27
NCT04339777: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Recruiting
2
66
US
Busulfan test dose, Fludarabine, Busulfan, Alemtuzumab, Total body Irradiation, Allogeneic HSCT, Tacrolimus (Tacro), Mycophenolate mofetil (MMF), Cyclophosphamide (Cytoxan)
National Cancer Institute (NCI)
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
10/26
11/27
NCI-2017-01311, NCT03246906: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Recruiting
2
160
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Gengraf, Neoral, OL 27-400, Sandimmun, Sandimmune, SangCya, Mycophenolate Mofetil, Cellcept, MMF, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm
10/26
10/26
NCT05917522: Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

Recruiting
2
800
US
Abatacept, Orencia, Standard of Care at US Transplant Centers
National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant
07/27
07/29
NCT05303727: Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not yet recruiting
2
64
RoW
Anti Thymocyte Globulin, ATG, Fludarabine, Fludara, Cyclophosphamide injection, CTX, Topotecan, Topotecan Hydrochloride, Melphalan, Alkeran, Thiotepa, thiophosphoramide, Busulfan, Busulfex, Cyclosporine, Sandimmune, Tacrolimus, Prograf, Mycophenolate Mofetil, Cellcept, Methotrexate, amethopterin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neuroblastoma
08/27
08/27
NCT05805605: Allo HSCT Using RIC and PTCy for Hematological Diseases

Recruiting
2
56
US
Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil, (MMF)
Masonic Cancer Center, University of Minnesota
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
10/27
10/28
NCT02579967: Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Recruiting
2
254
US
Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L, GVHD Prophylaxis, Allo BMT
National Cancer Institute (NCI)
Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases, Autoimmune Lymphoproliferative, Lymphoproliferative Disorders
12/27
12/28
NCT04883619 / 2020-005568-79: A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis

Not yet recruiting
2
80
US
Placebo, Nipocalimab, JNJ-80202135, M281, Standard-of-care treatment
Janssen Research & Development, LLC, Janssen Research & Development, LLC
Lupus Nephritis
02/28
02/28
NCT05884333: Cord Blood Transplant in Adults With Blood Cancers

Recruiting
2
54
US
Conditioning Chemotherapy, Cord blood graft
Memorial Sloan Kettering Cancer Center
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
05/28
05/28
NCT00882895: Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Active, not recruiting
2
18
US
Stem cell infusion, TLI, Anti-thymocyte globulin, ATG, Atgam, Thymoglobulin, Solumedrol, Medrol, Solu-Medrol, Tacrolimus, FK-506, Prograf, Advagraf, Protopic, Mycophenolate mofetil, MMF, CellCept, Myfortic
Washington University School of Medicine
Lymphoma, Non-Hodgkin
06/28
06/28
ALL IN LUNG, NCT06033196: Tocilizumab in Lung Transplantation

Recruiting
2
350
Canada, US
Tocilizumab, ACTEMRA, Placebo for Tocilizumab
National Institute of Allergy and Infectious Diseases (NIAID)
Lung Transplant
01/29
01/29
ADVANTage, NCT06055608: Advancing Transplantation Outcomes in Children

Recruiting
2
200
Canada, US
Sirolimus, AY 22-989, Rapamune, Rapamycin, Belatacept, Nulojix, Mycophenolate Mofetil, CellCept, MMF, Tacrolimus (Group1), FK-506, FR-900506, Prograf, Anti-Thymocyte Globulin (ATG), Tacrolimus (Group 2)
National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant
11/28
11/28
NCT05907746: Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency

Recruiting
2
32
US
Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide, Total Body Irradiation, Hematopoietic Cell Transplant, JSP191, Cyclophosphamide, Fludarabine
National Cancer Institute (NCI)
GATA2, Immunodeficiency
07/31
07/31
2013-000999-15: The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial

Not yet recruiting
1/2
16
Europe
Mreg_UKR, Prednisolone, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid, Suspension for injection, , tbd
University Hospital Regensburg, European Commission
Kidney allograft rejection following living-donor renal transplantation., Kidney graft rejection in patients receiving a kidney transplant from a living organ donor., Body processes [G] - Immune system processes [G12]
 
 
2019-002186-36: Treatment of acute graft-versus-host disease after allogeneic stem cell transplantation with placenta derived decidua stroma cells (DSC) compared with best available treatment (BAT).

Not yet recruiting
1/2
56
Europe
Decidua Stroma Cells, DSC, L01XE18, L04AA, L04AX03, L04AA06, L01XE10, L04AA10, L04AB01, L04AB02, Solution for injection/infusion, , Powder and solution for solution for injection, Tablet, Powder and solvent for dispersion for injection, Solution for blood fraction modification, Jakavi, Entyvio, Methotrexate, Cellcept, Afinitor, Rapamune, Enbrel, Remicade, Extracorporeal photophersis, Methoxalen
Uppsala University Hospital, Uppsala University Hospital, KFUE Hæmatologi, Swedish Research Council
Steroid refractory acute GVHD Kortison refraktär akut GVHD, Acute graft-versus-host reaction after allogeneic stem cell transplantation not responding to steroid treatment. Akut transplantat-mot-värd reaktion som inte svarar på kortison behandling., Diseases [C] - Immune System Diseases [C20]
 
 
NCT01033552: Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Completed
1/2
32
US
Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Anti-thymocyte globulin, ATG, Myeloablative Busulfan, Mesenchymal stem cell transplantation, MSCT, Total body irradiation, Bone marrow or umbilical cord blood (UCG) stem cell transplantation, UCBSCT
Masonic Cancer Center, University of Minnesota
Epidermolysis Bullosa
08/21
08/21
NCT03441958: ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

Active, not recruiting
1/2
20
Canada
ECT-001 (UM171) expanded cord blood
Ciusss de L'Est de l'Île de Montréal, ExCellThera inc., Centre C3i
Multiple Myeloma
10/23
10/25
TASK, NCT02711826: Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Completed
1/2
14
US
Polyclonal Regulatory T Cells, Polyclonal Tregs, polyTregs, Everolimus, Zortress, Tacrolimus, FK-506, FR-900506, Prograf, Mycophenolate mofetil, Cellcept, MMF, Mycophenolic acid, Myfortic, MPA, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Biopsy, Kidney, Kidney Biopsy, Blood Draw, Phlebotomy, Venipuncture, Leukapheresis, leukocytapheresis, IS regimen conversion, Everolimus Conversion
National Institute of Allergy and Infectious Diseases (NIAID), Clinical Trials in Organ Transplantation
Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
08/23
08/23
NCT04066114: Treg Modulation With CD28 and IL-6 Receptor Antagonists

Completed
1/2
10
US
lulizumab pegol, BMS-931699, antithymocyte globulin (rabbit), ATG (rabbit), Thymoglobulin®, methylprednisolone, Solu-Medrol ®, tocilizumab, Actemra®, Prednisone, prednisone tablets, Rayos®, everolimus, Zortress®, belatacept, Nulojix®, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, Myfortic®
National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, Clinical Trials in Organ Transplantation
Living-Donor Kidney Transplant, Kidney Transplant Recipients
09/23
09/23
NCT04622956: GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

Recruiting
1/2
47
RoW
Methotrexate Injectable Solution, Fauldmetro [Libbs]
University of Sao Paulo General Hospital, Libbs Farmacêutica LTDA
Graft Vs Host Disease, Hematopoietic Neoplasm
12/23
12/25
NCI-2018-01788, NCT03670966: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Suspended
1/2
30
US
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Cyclophosphamide, (-)-Cyclophosphamide, Asta B 518, B-518, WR-138719, Total-Body Irradiation, Total Body Irradiation, SCT_TBI, Whole Body Irradiation, Whole-Body Irradiation, TBI, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Bone Marrow Transplantation, Bone Marrow Grafting, BMT, Mycophenolate Mofetil, 115007-34-6, MMF, Cellcept, Recombinant Granulocyte Colony-Stimulating Factor, 143011-72-7, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Fludarabine Phosphate, 2-F-ara-AMP, Beneflur, Fludara, Fludarabine-5''-Monophosphate, SH T 586, Tacrolimus, Prograf, Protopic, FK 506, FK-506, Tacforius, Bone Marrow Aspiration and Biopsy, Biospecimen Collection, Biological Sample Collection
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
06/25
03/27
NCT03842696: Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
1/2
49
US
Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)
Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
06/25
06/26
NCI-2017-01069, NCT03192397: Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Active, not recruiting
1/2
35
US
Allogeneic Hematopoietic Stem Cell Transplantation, allogeneic stem cell transplantation, HSC, HSCT, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Alkeran, Alkerana, Evomela, Mycophenolate Mofetil, Cellcept, MMF, Sirolimus, Rapamune, Total-Body Irradiation, TOTAL BODY IRRADIATION, Whole-Body Irradiation
Roswell Park Cancer Institute
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission, Graft Versus Host Disease, Hodgkin Lymphoma, Minimal Residual Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Severe Aplastic Anemia, Waldenstrom Macroglobulinemia
08/23
05/27
NCT06279494: Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

Not yet recruiting
1/2
6
NA
Sirolimus, Abatacept, MMF, ATG
Peking University People's Hospital
Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia
06/24
03/25
NCT03128996: Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Recruiting
1/2
29
US
RIC regimen, Transplant Preparative Regimen, Transplant Conditioning Regimen, GVHD prophylaxis regimen, Graft versus Host Disease prophylaxis regimen
Washington University School of Medicine
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
04/24
04/26
NCT01701986: Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Completed
1/2
64
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic BMT, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Clofarabine, Clofarex, Clolar, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Mycophenolate Mofetil, Cellcept, MMF, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Pharmacological Study, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
06/24
06/24
NCT05115630: Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Recruiting
1/2
24
US
Cyclophosphamide, Mesna, Filgrastim, Melphalan, Fludarabine phosphate, Tacrolimus, Mycophenolate mofetil, Total Body Irradiation One Dose
M.D. Anderson Cancer Center
Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
06/24
06/24
NCT04022239: Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Recruiting
1/2
25
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Bendamustine, SDX-105, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, CellCept, MMF, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid System Neoplasm
07/25
07/25
NCI-2018-01607, NCT03247088: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Active, not recruiting
1/2
74
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim, Filgrastim-aafi, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Fludarabine, Fluradosa, Mycophenolate Mofetil, CellCept, MMF, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/24
12/24
DSC-BROMS-1, NCT04118556: Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT

Recruiting
1/2
50
Europe
Decidua Stroma Cells (DSC), Best available Treatment (BAT), ECP, Everolimus, Sirolimus, Etanercept, Vedolizumab, Ruxolitinib, Infliximab.
Mats Remberger, The Swedish Research Council
GVHD, Acute
12/24
12/29
NCT05250362: Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation

Recruiting
1/2
56
RoW
Allogeneic Hematopoietic Stem Cell Transplantation
Sichuan University
Hematologic Malignancy
02/25
12/25
NCT05589896: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Recruiting
1/2
12
US
Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Busuflex, Fludara, TBI, Pre-transplant conditioning - Reduced Intensity (RIC), Cytoxan, Mesnex, Post-transplant treatment, CellCept, Filgrastim
Ossium Health, Inc., Center for International Blood and Marrow Transplant Research
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia
08/25
08/25
CLAMP, NCT05049863: Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate ( Trial)

Recruiting
1/2
36
US
Mycophenolate Mofetil, MMF, Cellcept, Allopurinol, Zyloprim, Aloprim, Irinotecan, Onivyde, Camptosar
Washington University School of Medicine
Small-cell Lung Cancer, Small Cell Lung Carcinoma
04/25
10/25
NCT03983850: Optimizing PTCy Dose and Timing

Recruiting
1/2
400
US
Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus
National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS)
Graft Versus Host Disease, Hematologic Neoplasms
05/25
05/26
NCT03128034: 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Suspended
1/2
75
US
Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Gengraf, Neoral, OL 27-400, Sandimmun, Sandimmune, SangCya, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Cellcept, MMF, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Pharmacological Study, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Total Body Irradiation, Whole-Body Irradiation, TBI, Whole Body Irradiation, SCT_TBI
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
01/23
03/27
NCT01203722: Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Recruiting
1/2
100
US
Fludarabine, Cytoxan, High-dose Cytoxan, Total Body Irradiation, TBI, Allogeneic Blood or Marrow Transplant, BMT, Peripheral Blood Stem Cell Transplant, PBSCT, Mycophenolate Mofetil, MMF, Sirolimus, Tacrolimus
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
Hematologic Malignancies
09/25
12/25
NCT05807932: Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Recruiting
1/2
38
Europe
Venetoclax, Amsacrine, Ara-C, Tacrolimus, Mycophenolate Mofetil
Heinrich-Heine University, Duesseldorf, Koordinierungszentrum für Klinische Studien - Duesseldorf
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
01/26
01/28
NCT04959175: Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Recruiting
1/2
320
US
Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI)
National Cancer Institute (NCI)
Hematologic Neoplasms
04/27
04/27
NCT05436418: The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting
1/2
240
US
Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
National Cancer Institute (NCI)
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
06/27
07/27
NCT04083183: Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Suspended
1/2
40
US
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10, Astatine At 211 MAb BC8-B10, At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Fludarabine, 2-Fluorovidarabine, 21679-14-1, 9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine, 9-Beta-D-arabinofuranosyl-2-fluoroadenine, Fluradosa, 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, 21679-14-1, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclostin, Cyclostine, Cytoxan, WR-138719, Lapine T-Lymphocyte Immune Globulin, Anti-thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Total-Body Irradiation, TBI, TOTAL BODY IRRADIATION, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, Mycophenolate Mofetil, Cellcept, MMF, 115007-34-6, Sirolimus, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Bone Marrow Aspiration, Biospecimen Collection
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Non-Malignant Neoplasm
01/28
01/28
NCT05327023: Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Recruiting
1/2
430
US
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
National Cancer Institute (NCI)
Hematologic Neoplasms
07/28
07/29
 

Download Options